Insider trade

CFO sold ~$2.93M of JNJ shares in the open market

Traded Feb 17, 2026 · Filed Feb 19, 2026

Johnson & JohnsonJNJ

~$2.93M
Reported value · 12K sh @ $242.87: 39K
Holds after · shares reported: +6.3%
stock since the trade · S&P 500 +11.9%, $243.33 → $258.66 on Oct 1

Why it stands out

The money chief of Johnson & Johnson sold $2.93M of Johnson & Johnson shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 17, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 19, 2026

CFO$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,930,469

Shares × reported transaction price

Timing vs results

27 days after results of Jan 21, 2026, 56 days before results of Apr 14, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $243.33 on Feb 17, 2026, within 1% of its 52-week high, after a 17% rise over the previous 30 trading days

52-week range $146.36 (May 14, 2025) to $244.55 (Feb 12, 2026), 99% of the way up, from 251 adjusted closes. 30 trading days earlier: $207.35 on Jan 2, 2026. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Rybrevant Faspro on Feb 13, 2026, 4 days before this trade.

Biologic approved. Active ingredient: Amivantamab and Hyaluronidase-Lpuj. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-1.4%	+0.7%	-2.1%
30 days	-4.7%	-4.3%	-0.4%
90 days	-7.1%	+8.3%	-15.4%
180 days	+9.8%	+12.1%	-2.3%

Past results only. Not a forecast.

Source receipt

Record ID: 0000200406-26-000041
Filed / recorded: Feb 19, 2026, 2:12 AM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: JOHNSON & JOHNSON
Issuer CIK: 200406
Ticker: JNJ
Reporting person: Joseph J Wolk
Relationship: Officer
Officer title: Exec VP, CFO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Feb 17, 2026
Transaction code: S
Shares / units: 12,066
Price per share: $242.87
Acquired / disposed: Disposed (D)
Shares owned after: 38,961
Ownership form: Direct
Amendment: No

Footnotes from the filing

This transaction was executed in multiple trades at prices ranging from $242.85 to $242.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Around the same time

Veterans Affairs awarded7mo ago

$20Kcommitted so far

Balversa 4 mg

The Department of Veterans Affairs has already agreed to pay Johnson & Johnson $20K. The job runs until Mar 24, 2026.

Why it stands out Official record

7mo ago

75.26Derivative units · @ $166.10

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record

7mo ago

206.49Derivative units · @ $242.14

Compensation award — excluded from discretionary-purchase analysis.

Why it stands out Official record